Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11643397 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(3 years from now) | |
US8324208 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Dec, 2028
(4 years from now) | |
US11117871 | GLAXOSMITHKLINE | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof |
Mar, 2038
(13 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8815884 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(3 years from now) | |
US8557834 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(3 years from now) | |
US11649217 | GLAXOSMITHKLINE | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof |
Mar, 2038
(13 years from now) |
Jesduvroq is owned by Glaxosmithkline.
Jesduvroq contains Daprodustat.
Jesduvroq has a total of 6 drug patents out of which 0 drug patents have expired.
Jesduvroq was authorised for market use on 01 February, 2023.
Jesduvroq is available in tablet;oral dosage forms.
Jesduvroq can be used as a method of treating anemia, treatment of anemia due to chronic kidney disease.
Drug patent challenges can be filed against Jesduvroq from 01 February, 2027.
The generics of Jesduvroq are possible to be released after 13 March, 2038.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 01, 2028 |
Drugs and Companies using
DAPRODUSTAT ingredient